Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases
Federica Marmorino(University of Pisa), Chiara Cremolini(University of Pisa), Massimo Milione(Fondazione IRCCS Istituto Nazionale dei Tumori), Mirella Giordano(University of Pisa), Gabriella Fontanini(University of Pisa), Giacomo Mazzoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Marzia Del Re(Saint Camillus International University of Health and Medical Sciences), Paolo Manca(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Prisciandaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandra Boccaccino(Ospedale "Santa Maria delle Croci" di Ravenna), Antonia Martinetti(Cochlear (Australia)), Gianluca Masi(University of Pisa), Stefania Crucitta(Meyer Children's Hospital), Elisa Sottotetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Martina Carullo(University of Pisa), Carlo Sposito(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Carlotta Antoniotti(University of Pisa), Marta Maria Valenti, Romano Danesi(University of Milan), Veronica Conca(University of Pisa)
Cited by 28
Related Papers
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k